# Lecture 01: Bone and Joint Structure ## Unit 2.10: Musculoskeletal and Dermatology --- ## Learning Objectives By the end of this lecture, students will be able to: 1. Describe the structure and composition of bone tissue 2. Explain the process of bone formation and remodeling 3. Describe the types of joints and their structure 4. Explain the structure of articular cartilage 5. Describe the regulation of calcium and phosphorus homeostasis 6. Explain the pathophysiology of metabolic bone diseases --- ## Lecture Outline ### I. Bone Composition and Structure Bone tissue represents a remarkable composite material consisting of approximately 35% organic matrix and 65% inorganic mineral content, each component contributing distinct mechanical properties to the skeleton. The organic matrix provides flexibility and tensile strength through its predominantly collagenous composition, with type I collagen comprising approximately 90% of this organic component and serving as the structural framework upon which mineralization occurs. The inorganic mineral component, primarily hydroxyapatite with the chemical formula Ca10(PO4)6(OH)2, confers rigidity and compressive strength to withstand mechanical loading. This biphasic composition allows bone to resist both tensile and compressive forces while maintaining sufficient flexibility to prevent brittle fracture. The cellular components of bone tissue comprise four distinct cell types, each originating from specific progenitor populations and serving specialized functions in bone homeostasis. Osteoblasts arise from mesenchymal stem cells and function as the primary bone-forming cells, synthesizing osteoid matrix and initiating mineralization through secretion of alkaline phosphatase and matrix vesicles. Osteocytes represent the most abundant bone cell type, derived from osteoblasts that become entrapped within the mineralized matrix, where they function as mechanosensors and coordinate cellular signaling throughout the bone tissue network. Osteoclasts originate from hematopoietic monocyte-macrophage precursors and serve as the primary bone-resorbing cells, utilizing acidification and proteolytic enzymes to degrade both mineral and organic components of bone matrix. Bone lining cells represent quiescent osteoblasts that cover inactive bone surfaces and regulate ion flux between bone and extracellular fluid. The macroscopic architecture of bone comprises two distinct structural types distributed throughout the skeleton according to mechanical demands. Cortical or compact bone forms the dense outer shell of bones, comprising approximately 80% of total skeletal mass and predominating in the diaphyses of long bones where resistance to bending and torsion is paramount. Trabecular or cancellous bone exhibits a porous, honeycomb-like structure comprising approximately 20% of skeletal mass, located primarily at the metaphyses and epiphyses of long bones and within vertebral bodies where it provides strength with minimal weight. The microscopic organization further distinguishes woven bone, characterized by disorganized collagen fiber arrangement typical of rapidly formed bone in fetal development or fracture repair, from mature lamellar bone exhibiting highly organized concentric layers. The fundamental structural unit of cortical bone is the osteon or Haversian system, consisting of concentric lamellae of mineralized bone surrounding a central Haversian canal containing blood vessels and nerves. Osteocytes reside within lacunae distributed throughout the lamellae, connected to one another and to the central canal through an extensive network of canaliculi that permit nutrient exchange and intercellular communication. Volkmann's canals traverse the bone perpendicular to Haversian canals, providing interconnections between osteons and communication with the periosteal and endosteal surfaces. This intricate vascular and cellular network ensures metabolic support for osteocytes and facilitates the mechanosensory function of bone tissue. Panel A: Cross-sectional diagram of cortical bone showing the osteon structure with concentric lamellae, central Haversian canal containing blood vessels, osteocytes within lacunae, and canaliculi radiating outward connecting adjacent cells. Panel B: Comparison of cortical (compact) and trabecular (spongy) bone architecture showing dense cortical bone surrounding a porous trabecular network with marrow spaces. Panel C: Microscopic view of the four bone cell types - cuboidal osteoblasts lining the bone surface, stellate osteocytes within lacunae, multinucleated osteoclasts in resorption pits, and flat bone lining cells covering quiescent surfaces. Panel D: Three-dimensional reconstruction of trabecular bone showing interconnected plates and rods of mineralized bone with marrow-filled spaces. --- ### II. Bone Formation and Remodeling Ossification occurs through two distinct developmental pathways that differ fundamentally in their mechanisms but ultimately produce structurally and biochemically identical mature bone tissue. Intramembranous ossification involves the direct transformation of mesenchymal tissue into bone without a cartilaginous intermediate, occurring in the flat bones of the skull, facial bones, and clavicle where mesenchymal stem cells differentiate directly into osteoblasts that deposit osteoid matrix. Endochondral ossification, by contrast, requires the formation of a hyaline cartilage template that is progressively replaced by bone tissue, occurring in long bones, vertebrae, and the base of the skull. This latter mechanism permits longitudinal bone growth through the activity of epiphyseal growth plates until skeletal maturity. The endochondral ossification process proceeds through a highly organized sequence of events observable within the epiphyseal growth plate, where distinct zones represent progressive stages of chondrocyte differentiation and matrix transformation. The resting zone at the epiphyseal end contains reserve cartilage with randomly distributed chondrocytes that serve as a stem cell reservoir. The proliferative zone exhibits active chondrocyte division producing columns of flattened cells that elongate the cartilage template. In the hypertrophic zone, chondrocytes undergo dramatic enlargement and begin secreting factors that promote vascular invasion and mineralization. The zone of calcification sees deposition of calcium salts within the cartilage matrix, followed by chondrocyte apoptosis and vascular invasion in the zone of ossification where osteoblasts deposit bone on the calcified cartilage scaffold. Bone remodeling represents a continuous physiological process occurring throughout life, involving the coordinated activity of osteoclasts and osteoblasts in discrete anatomical units termed basic multicellular units. The remodeling cycle begins with an activation phase lasting several days, during which osteoclast precursors are recruited to the bone surface and differentiate into mature osteoclasts. The resorption phase spans approximately two to four weeks as osteoclasts excavate a resorption pit by secreting hydrogen ions and proteolytic enzymes. A reversal phase of one to two weeks follows, characterized by apoptosis of osteoclasts and recruitment of osteoblast precursors to the resorption site. The formation phase requires four to six months as osteoblasts deposit osteoid matrix that subsequently mineralizes, ultimately restoring bone mass. The quiescent phase of variable duration follows until the next remodeling cycle is initiated. Multiple hormonal and local factors regulate the balance between bone formation and resorption, determining whether the skeleton gains or loses mass over time. Parathyroid hormone exerts complex effects on bone, with intermittent exposure paradoxically stimulating anabolic osteoblast activity while continuous exposure promotes catabolic osteoclast-mediated resorption. Vitamin D metabolites, particularly 1,25-dihydroxyvitamin D, increase calcium absorption from the intestine and modulate bone cell activity. Calcitonin secreted by thyroid C cells directly inhibits osteoclast function, though its physiological significance in humans remains debated. Estrogen plays a critical protective role by inhibiting osteoclast differentiation and activity, explaining the accelerated bone loss following menopause. Glucocorticoids at pharmacological doses decrease bone formation while increasing resorption, accounting for osteoporosis as a common complication of chronic corticosteroid therapy. Mechanical loading sensed by osteocytes stimulates bone formation in regions of high stress. Panel A: Diagram of the bone remodeling cycle showing the sequential phases of activation (osteoclast precursor recruitment), resorption (osteoclast-mediated bone removal creating a resorption pit), reversal (transition between cell types), formation (osteoblast bone deposition), and quiescence (resting bone surface). Panel B: Histological section through an epiphyseal growth plate demonstrating the distinct zones: resting zone with scattered chondrocytes, proliferative zone with columnar cell arrangement, hypertrophic zone with enlarged cells, and zone of ossification with vascular invasion and bone deposition. Panel C: Schematic of the RANK/RANKL/OPG signaling pathway showing osteoblast-derived RANKL binding to RANK on osteoclast precursors to stimulate differentiation, and OPG acting as a decoy receptor to inhibit this interaction. Panel D: Effects of various hormones on bone cells with PTH, vitamin D, estrogen, calcitonin, and glucocorticoids showing their stimulatory or inhibitory effects on osteoblasts and osteoclasts. --- ### III. RANK/RANKL/OPG Signaling System The receptor activator of nuclear factor kappa-B ligand (RANKL) signaling pathway represents the central molecular mechanism controlling osteoclast differentiation, activation, and survival, making it a critical therapeutic target for bone diseases. RANKL is a membrane-bound protein expressed primarily by osteoblasts, osteocytes, and activated T lymphocytes that binds to its cognate receptor RANK expressed on osteoclast precursors and mature osteoclasts. This ligand-receptor interaction triggers intracellular signaling cascades that promote osteoclast precursor fusion into multinucleated cells, activation of bone-resorbing machinery, and prolongation of osteoclast lifespan by inhibiting apoptosis. The essential role of this pathway is demonstrated by RANKL-deficient mice, which exhibit severe osteopetrosis due to complete absence of osteoclasts. Osteoprotegerin (OPG) functions as a soluble decoy receptor secreted by osteoblasts and other cells that binds RANKL with high affinity, preventing its interaction with RANK and thereby inhibiting osteoclast differentiation and activity. The ratio of RANKL to OPG expression determines the net balance between bone resorption and formation, with elevated RANKL/OPG ratios favoring osteoclastogenesis and bone loss. Multiple factors modulate this ratio, including hormones such as estrogen that increases OPG expression, and inflammatory cytokines like TNF-alpha and IL-1 that increase RANKL while suppressing OPG. Understanding this regulatory system has enabled development of denosumab, a monoclonal antibody against RANKL that effectively mimics OPG function and has revolutionized treatment of osteoporosis and bone metastases. Clinical applications of RANK/RANKL/OPG pathway modulation extend across multiple bone diseases characterized by excessive osteoclast activity. In osteoporosis, an elevated RANKL/OPG ratio contributes to accelerated bone resorption, particularly following estrogen withdrawal at menopause. Denosumab administration every six months effectively inhibits RANKL, reduces bone turnover markers, increases bone mineral density, and significantly decreases fracture risk at vertebral, hip, and nonvertebral sites. In malignancy-associated bone disease including bone metastases and multiple myeloma, tumor cells and stromal elements produce abundant RANKL that drives osteolytic destruction. Denosumab therapy reduces skeletal-related events including pathological fractures and need for radiation therapy. Paget disease of bone features dramatically increased osteoclast activity and bone turnover, though bisphosphonates that induce osteoclast apoptosis remain first-line therapy. The Wnt signaling pathway represents another critical regulatory system controlling osteoblast differentiation and bone formation, operating in parallel with the RANKL pathway. Wnt ligands bind to receptor complexes comprising LRP5/6 and Frizzled receptors, preventing degradation of intracellular beta-catenin, which translocates to the nucleus to activate transcription of osteoblastogenic genes. Sclerostin, produced almost exclusively by osteocytes, functions as an endogenous Wnt pathway inhibitor that suppresses bone formation. Mutations causing sclerostin deficiency result in high bone mass disorders, validating sclerostin as a therapeutic target. Romosozumab, a monoclonal antibody against sclerostin, represents a novel anabolic agent that simultaneously increases bone formation and decreases resorption. Additional growth factors including bone morphogenetic proteins (BMPs), transforming growth factor-beta (TGF-beta), insulin-like growth factor-1 (IGF-1), and fibroblast growth factors (FGF) modulate bone cell differentiation and activity through autocrine and paracrine mechanisms. Panel A: Molecular diagram of the RANK/RANKL/OPG pathway showing an osteoblast expressing membrane-bound RANKL, secreted OPG molecules, and an osteoclast precursor with RANK receptors, illustrating how RANKL-RANK binding promotes osteoclastogenesis while OPG-RANKL binding prevents this interaction. Panel B: Schematic of the Wnt signaling pathway in osteoblasts showing Wnt ligand binding to LRP5/6 and Frizzled receptors, beta-catenin stabilization and nuclear translocation, and sclerostin inhibition of this process. Panel C: Clinical applications showing denosumab mechanism of action in treating osteoporosis with before and after bone density images. Panel D: Comparison of bone remodeling balance in health versus disease states showing normal RANKL/OPG ratio versus elevated ratios in osteoporosis and metastatic bone disease. --- ### IV. Joint Structure and Classification Joints are classified according to their structural characteristics and degree of permitted movement, ranging from immovable fibrous connections to freely mobile synovial articulations. Synarthroses represent immovable joints characterized by fibrous tissue connecting adjacent bones, exemplified by the sutures between cranial bones that permit skull expansion during development but become progressively ossified in adulthood. Amphiarthroses exhibit limited mobility through cartilaginous or ligamentous connections, including the symphysis pubis and intervertebral discs where fibrocartilage permits modest deformation under load. Diarthroses or synovial joints constitute the most mobile joint type, featuring a fluid-filled joint cavity surrounded by a fibrous capsule and lined by synovial membrane. These freely movable joints predominate in the appendicular skeleton where range of motion is essential for locomotion and manipulation. Synovial joints share several essential structural components that enable low-friction movement while maintaining stability under physiological loads. Articular cartilage covers the opposing bone surfaces, providing a smooth, nearly frictionless bearing surface that distributes compressive forces and absorbs shock during joint loading. The synovial membrane lines the inner surface of the joint capsule except where articular cartilage is present, consisting of specialized cells that produce synovial fluid. The joint capsule comprises an outer fibrous layer continuous with the periosteum that provides structural support and an inner synovial layer. Synovial fluid fills the joint cavity, providing lubrication through hyaluronic acid content, delivering nutrients to the avascular articular cartilage, and removing metabolic waste products. Ligaments connect adjacent bones and resist excessive joint motion, providing static stability. Some joints additionally contain fibrocartilaginous structures such as menisci in the knee that increase congruence and distribute loads. Synovial joints demonstrate considerable structural diversity reflecting their distinct functional requirements, with classification based on the geometry of articular surfaces and permitted movements. Hinge joints such as the elbow and interphalangeal joints permit uniaxial motion restricted to flexion and extension around a single axis. Ball-and-socket joints including the hip and glenohumeral joints allow multiaxial motion including flexion, extension, abduction, adduction, and rotation. Pivot joints such as the atlantoaxial articulation permit rotation around a single axis. Saddle joints like the first carpometacarpal joint of the thumb exhibit biaxial motion through reciprocally concave-convex surfaces. Gliding or plane joints between carpal and tarsal bones permit sliding movements. Condyloid joints such as the radiocarpal articulation allow biaxial motion through ovoid surfaces. Joint stability depends upon the coordinated contributions of skeletal architecture, ligamentous restraints, muscular support, and other factors that vary in relative importance across different articulations. Bone congruence provides primary stability in joints such as the hip where the deep acetabulum encloses much of the femoral head. Ligaments furnish static stability by restricting motion beyond physiological limits, with their effectiveness depending on proper tension throughout the range of motion. Muscles crossing joints provide dynamic stability through active contraction that compresses articular surfaces and resists displacing forces. The joint capsule contains proprioceptive nerve endings that sense joint position and contribute to neuromuscular control. Negative intra-articular pressure relative to atmospheric pressure helps maintain apposition of articular surfaces. Disruption of any stabilizing element through injury or disease may result in joint instability, abnormal kinematics, accelerated cartilage wear, and ultimately degenerative arthritis. Panel A: Cross-sectional anatomy of a synovial joint (knee) showing articular cartilage covering bone ends, synovial membrane lining the joint capsule, synovial fluid within the joint cavity, fibrous joint capsule, collateral and cruciate ligaments, and menisci. Panel B: Comparison of joint classification types showing synarthrosis (skull suture with fibrous connection), amphiarthrosis (intervertebral disc with fibrocartilage), and diarthrosis (synovial joint with fluid-filled cavity). Panel C: Illustrations of synovial joint subtypes including hinge (elbow), ball-and-socket (hip), pivot (atlantoaxial), saddle (thumb CMC), and gliding (intercarpal) with arrows indicating permitted movements. Panel D: Components contributing to joint stability showing bone congruence, ligamentous restraints, muscle forces, and proprioceptive feedback in a schematic representation. --- ### V. Articular Cartilage Structure and Function Articular cartilage is a highly specialized connective tissue that covers the ends of bones in synovial joints, exhibiting unique composition and organization optimized for load-bearing and low-friction articulation. Water constitutes 65-80% of cartilage wet weight and plays an essential role in load distribution through pressurization during compression. Type II collagen comprises 15-20% of wet weight and provides tensile strength through a fibrillar network that resists deformation. Proteoglycans, predominantly aggrecan, constitute 5-10% of wet weight and confer compressive resistance through their highly negatively charged glycosaminoglycan chains that attract and retain water. Chondrocytes represent only approximately 2% of tissue volume but are responsible for synthesizing and maintaining all extracellular matrix components throughout life. The organization of articular cartilage demonstrates distinct zonal architecture extending from the articular surface to the underlying subchondral bone. The superficial or tangential zone comprises thin, flattened chondrocytes and collagen fibers oriented parallel to the articular surface, providing a smooth gliding surface with high tensile strength to resist shear forces. The transitional or middle zone contains more rounded chondrocytes and obliquely oriented collagen fibers, functioning as a bridge between superficial and deep zones. The deep or radial zone features large, rounded chondrocytes arranged in columns perpendicular to the surface, with vertically oriented collagen fibers anchoring to the calcified cartilage. The calcified cartilage zone interfaces with subchondral bone through interdigitations that anchor cartilage to bone. The tidemark represents a histologically distinct boundary demarcating the transition from uncalcified to calcified cartilage. The proteoglycan content of cartilage provides the tissue with its characteristic compressive stiffness and resilience through electrostatic and osmotic mechanisms. Aggrecan, the predominant cartilage proteoglycan, consists of a core protein with numerous covalently attached chondroitin sulfate and keratan sulfate glycosaminoglycan chains. Multiple aggrecan molecules associate with a hyaluronic acid backbone through link proteins, forming massive aggregates with molecular weights exceeding 200 million daltons. The sulfate and carboxyl groups on glycosaminoglycans carry fixed negative charges that attract mobile cations and water molecules, generating substantial osmotic swelling pressure. This swelling pressure is restrained by the collagen network, and compression forces water redistribution that generates hydrostatic pressure supporting the load. Upon load removal, the osmotic gradient drives water back into the matrix, restoring tissue dimensions. Articular cartilage exhibits several distinctive properties with important implications for joint function and pathology. The tissue is completely avascular, receiving all nutrition through diffusion from synovial fluid, which limits metabolic activity and regenerative capacity. Cartilage lacks nerve endings and therefore cannot directly sense pain, though nociceptors in surrounding structures respond to mechanical and chemical stimuli. Chondrocytes exhibit low metabolic activity and limited proliferative capacity, resulting in minimal intrinsic repair capability when damage occurs. Despite these limitations, healthy cartilage achieves remarkable durability, with friction coefficients of 0.001-0.01 that surpass any artificial bearing surface. The combination of boundary lubrication from surface molecules, fluid film lubrication from pressurized interstitial fluid, and elastohydrodynamic effects enables decades of nearly frictionless motion under enormous loads. Panel A: Zonal organization of articular cartilage showing the superficial zone with flat cells and horizontal collagen, transitional zone with rounded cells and oblique collagen, deep zone with columnar cells and vertical collagen, tidemark boundary, calcified cartilage, and subchondral bone plate. Panel B: Molecular structure of the collagen-proteoglycan network showing type II collagen fibrils interspersed with aggrecan molecules consisting of core proteins with attached glycosaminoglycan chains and link proteins connecting to hyaluronic acid. Panel C: Diagram illustrating cartilage load-bearing mechanism with water redistribution under compression, showing fixed negative charges on proteoglycans attracting cations and water, generating osmotic swelling pressure. Panel D: Functional properties of articular cartilage demonstrating avascular nutrition from synovial fluid, low friction coefficient, and chondrocyte distribution and morphology throughout the tissue depth. --- ### VI. Calcium and Phosphorus Homeostasis Calcium is distributed throughout the body with approximately 99% residing in bone as hydroxyapatite, where it serves both structural and reservoir functions. The remaining 1% is distributed between intracellular compartments and extracellular fluid, with intracellular calcium tightly regulated at nanomolar concentrations where it functions as a ubiquitous second messenger. Extracellular calcium exists in three forms: approximately 45% bound to albumin and other proteins, 10% complexed with anions such as citrate and phosphate, and 45% as free ionized calcium that represents the physiologically active fraction. Total serum calcium normally ranges from 8.5-10.5 mg/dL, while ionized calcium ranges from 4.5-5.3 mg/dL. Precise regulation of extracellular calcium is essential for neuromuscular function, coagulation, enzyme activity, and numerous other physiological processes. Three principal hormones coordinate calcium homeostasis through integrated actions on bone, kidney, and intestine. Parathyroid hormone (PTH), secreted by the parathyroid glands in response to decreased ionized calcium, acts rapidly to increase serum calcium through multiple mechanisms: stimulating osteoclast-mediated bone resorption, increasing renal calcium reabsorption in the distal tubule, and reducing phosphate reabsorption in the proximal tubule. PTH additionally stimulates renal 1-alpha-hydroxylase enzyme activity, increasing production of active vitamin D. Calcitriol (1,25-dihydroxyvitamin D), the active vitamin D metabolite, increases intestinal absorption of both calcium and phosphate, and at high concentrations may enhance bone resorption. Calcitonin, secreted by thyroid C cells in response to hypercalcemia, directly inhibits osteoclast activity and promotes renal calcium excretion, though its physiological significance in adult humans remains uncertain. The actions of PTH on target organs are precisely coordinated to restore normocalcemia when serum calcium falls. In bone, PTH binding to receptors on osteoblasts and osteocytes increases RANKL expression while decreasing OPG, indirectly stimulating osteoclast differentiation and bone resorption to release calcium and phosphate. In the kidney, PTH increases calcium reabsorption through upregulation of calcium channels and transporters in the distal convoluted tubule while simultaneously decreasing phosphate reabsorption in the proximal tubule through internalization of sodium-phosphate cotransporters, resulting in phosphaturia that prevents calcium phosphate precipitation. PTH also stimulates 1-alpha-hydroxylase activity in proximal tubular cells, increasing conversion of 25-hydroxyvitamin D to active 1,25-dihydroxyvitamin D. The net effect on the gastrointestinal tract is indirect, mediated through increased vitamin D activity enhancing intestinal calcium and phosphate absorption. Vitamin D undergoes sequential hydroxylation reactions to generate its biologically active form. Initial synthesis occurs in skin where ultraviolet B radiation converts 7-dehydrocholesterol to cholecalciferol (vitamin D3), or alternatively dietary vitamin D (D2 or D3) is absorbed from the intestine. The first hydroxylation occurs in the liver by 25-hydroxylase, producing 25-hydroxyvitamin D (calcidiol), the primary circulating form used to assess vitamin D status. The second hydroxylation in the kidney by 1-alpha-hydroxylase produces 1,25-dihydroxyvitamin D (calcitriol), the active hormone that binds to vitamin D receptors functioning as a nuclear transcription factor. Fibroblast growth factor 23 (FGF23), secreted by osteocytes in response to elevated phosphate, represents an additional regulatory hormone that decreases renal phosphate reabsorption and suppresses 1-alpha-hydroxylase activity, preventing hyperphosphatemia. Panel A: Distribution of calcium in the body showing 99% in bone as hydroxyapatite, 0.9% intracellular, and 0.1% extracellular (divided into protein-bound, complexed, and ionized fractions), with a pie chart illustrating extracellular calcium forms. Panel B: Integrated calcium homeostasis showing PTH and vitamin D actions on bone (resorption), kidney (calcium reabsorption, phosphate excretion, vitamin D activation), and intestine (calcium absorption), with arrows indicating stimulatory effects and resulting serum calcium changes. Panel C: PTH secretion and action diagram showing parathyroid glands responding to low calcium with PTH release, and PTH effects on RANK/RANKL in bone, tubular transporters in kidney, and vitamin D synthesis. Panel D: Vitamin D metabolism pathway from UV exposure and dietary sources through hepatic 25-hydroxylation, renal 1-alpha-hydroxylation regulated by PTH and FGF23, to active calcitriol and its effects on target tissues. --- ### VII. Osteoporosis Osteoporosis is defined as a systemic skeletal disease characterized by low bone mass and microarchitectural deterioration of bone tissue, leading to enhanced bone fragility and increased fracture risk. Primary osteoporosis encompasses postmenopausal osteoporosis (Type 1), resulting from accelerated bone loss following estrogen withdrawal, and age-related or senile osteoporosis (Type 2), reflecting the cumulative effects of aging on bone formation and resorption balance. Secondary osteoporosis occurs when bone loss is attributable to specific medical conditions or medications, including glucocorticoid therapy, hyperthyroidism, hyperparathyroidism, hypogonadism, malabsorption syndromes, and chronic kidney disease. Osteoporosis represents a major public health concern, with fragility fractures causing substantial morbidity, mortality, and healthcare costs in aging populations. Risk factors for osteoporotic fracture include both non-modifiable characteristics and potentially modifiable behaviors and conditions. Non-modifiable factors include advanced age, female sex, Caucasian or Asian ethnicity, personal history of fracture after age 50, family history of osteoporosis or hip fracture, and small body frame. Modifiable risk factors encompass low dietary calcium and vitamin D intake, sedentary lifestyle, cigarette smoking, excessive alcohol consumption (more than three drinks daily), and low body weight. Medical conditions predisposing to osteoporosis include inflammatory diseases such as rheumatoid arthritis, endocrine disorders including hyperthyroidism and hyperparathyroidism, gastrointestinal diseases causing malabsorption, and chronic kidney disease. Medications contributing to bone loss include glucocorticoids (the most common cause of secondary osteoporosis), anticonvulsants, aromatase inhibitors, and proton pump inhibitors with long-term use. Diagnosis of osteoporosis relies primarily on bone mineral density (BMD) measurement by dual-energy X-ray absorptiometry (DXA), typically at the lumbar spine, femoral neck, and total hip. Results are expressed as T-scores representing standard deviations from the mean BMD of a young adult reference population. A T-score of -1.0 or above is considered normal, while T-scores between -1.0 and -2.5 indicate osteopenia, and T-scores of -2.5 or below establish the diagnosis of osteoporosis. A diagnosis of severe or established osteoporosis requires a T-score of -2.5 or below plus the presence of one or more fragility fractures. The Fracture Risk Assessment Tool (FRAX) integrates BMD with clinical risk factors to estimate 10-year probability of major osteoporotic fracture and hip fracture, assisting treatment decisions when BMD alone does not clearly indicate intervention. Treatment of osteoporosis includes both pharmacological and non-pharmacological approaches aimed at reducing fracture risk. Adequate calcium intake (1000-1200 mg daily) and vitamin D supplementation (800-2000 IU daily to maintain serum 25-hydroxyvitamin D above 30 ng/mL) provide essential substrate for bone mineralization. Weight-bearing and resistance exercise improve muscle strength and balance, reducing fall risk while providing mechanical stimulus for bone formation. Antiresorptive medications including bisphosphonates (alendronate, risedronate, zoledronic acid), denosumab (RANKL inhibitor), and selective estrogen receptor modulators (raloxifene) reduce bone resorption and fracture risk. Anabolic agents including teriparatide (PTH analog), abaloparatide (PTHrP analog), and romosozumab (sclerostin inhibitor) stimulate bone formation and are particularly useful for patients with severe osteoporosis or those who have failed antiresorptive therapy. Fall prevention strategies including home safety assessment, vision correction, and medication review reduce fracture risk independent of bone density. Panel A: DXA scan interpretation showing bone mineral density measurement at lumbar spine and femoral neck with corresponding T-score calculation, normal versus osteoporotic appearance, and WHO diagnostic criteria (T-score greater than or equal to -1.0 normal, -1.0 to -2.5 osteopenia, less than or equal to -2.5 osteoporosis). Panel B: Comparison of normal trabecular bone architecture versus osteoporotic bone showing loss of trabecular connectivity, thinning of remaining trabeculae, and decreased cortical thickness. Panel C: Osteoporosis treatment algorithm flowchart beginning with risk assessment, followed by lifestyle modifications for all patients, and pharmacological therapy selection based on fracture risk and previous treatment response. Panel D: Mechanism of action diagram for major osteoporosis medications showing bisphosphonates inducing osteoclast apoptosis, denosumab blocking RANKL, teriparatide stimulating osteoblasts, and romosozumab inhibiting sclerostin. --- ### VIII. Other Metabolic Bone Diseases Osteomalacia and rickets represent disorders of defective bone mineralization, with rickets referring to the disease in children before epiphyseal closure and osteomalacia to the equivalent condition in adults. The most common cause is vitamin D deficiency, resulting from inadequate sun exposure, dietary insufficiency, malabsorption, or impaired hepatic or renal hydroxylation. Phosphate depletion from dietary deficiency, renal wasting, or oncogenic osteomalacia (tumor-secreted FGF23) represents another important etiology. Characteristic laboratory findings include low or low-normal serum calcium and phosphate, elevated alkaline phosphatase reflecting increased osteoblast activity, and elevated PTH levels secondary to hypocalcemia. In children, rickets manifests with skeletal deformities including frontal bossing, rachitic rosary (enlarged costochondral junctions), bowing of long bones, and widened wrists and ankles with delayed growth. Treatment consists of vitamin D and calcium supplementation, or phosphate replacement when appropriate. Paget disease of bone is a focal disorder of accelerated bone remodeling characterized by excessive osteoclast-mediated resorption followed by disorganized osteoblast-mediated formation, resulting in enlarged, structurally abnormal bone. The disease progresses through three phases: an initial lytic phase with predominant osteoclast activity and bone destruction, a mixed phase with concurrent resorption and formation, and a late sclerotic phase with dense, disorganized bone. Common complications include bone pain, pathological fractures through weakened bone, skeletal deformity, hearing loss from temporal bone involvement, and rarely high-output cardiac failure from increased vascularity or osteosarcoma transformation. Laboratory findings typically reveal markedly elevated serum alkaline phosphatase with normal calcium and phosphate levels. Treatment with bisphosphonates effectively suppresses disease activity, with zoledronic acid providing prolonged remission after a single infusion. Primary hyperparathyroidism results from autonomous PTH secretion, most commonly from a parathyroid adenoma (85% of cases), with parathyroid hyperplasia and carcinoma accounting for the remainder. The characteristic biochemical profile includes hypercalcemia, elevated or inappropriately normal PTH (which should be suppressed in hypercalcemia), and hypophosphatemia due to renal phosphate wasting. Classical clinical manifestations described as "stones, bones, groans, and psychiatric overtones" encompass nephrolithiasis (calcium-containing kidney stones), osteitis fibrosa cystica (bone disease with subperiosteal resorption, brown tumors, and pathological fractures), gastrointestinal symptoms (constipation, pancreatitis, peptic ulcer), and neuropsychiatric manifestations (depression, cognitive impairment). However, most patients today present with asymptomatic hypercalcemia discovered on routine laboratory testing. Surgical parathyroidectomy is the definitive treatment for symptomatic disease or when specific criteria are met in asymptomatic patients. Renal osteodystrophy encompasses the spectrum of bone diseases occurring in chronic kidney disease (CKD), resulting from the complex interplay of impaired vitamin D activation, phosphate retention, secondary hyperparathyroidism, and altered bone responsiveness to PTH. Decreased renal 1-alpha-hydroxylase activity leads to reduced calcitriol production, diminishing intestinal calcium absorption and bone mineralization. Phosphate retention stimulates FGF23 and PTH secretion while directly suppressing calcitriol synthesis. High-turnover bone disease (osteitis fibrosa) predominates when secondary hyperparathyroidism is inadequately controlled, while low-turnover disease (adynamic bone disease) may result from excessive suppression of PTH. Treatment requires a multifaceted approach including phosphate binders to reduce intestinal phosphate absorption, active vitamin D analogs to suppress PTH and improve calcium balance, and calcimimetics (cinacalcet) that activate calcium-sensing receptors on parathyroid cells to reduce PTH secretion. Panel A: Radiographic features of Paget disease showing cortical thickening, coarsened trabecular pattern, and bone enlargement in the pelvis and femur, with characteristic "picture frame" vertebra and "cotton wool" skull appearance. Panel B: Clinical and radiographic manifestations of rickets including frontal bossing, rachitic rosary at costochondral junctions, metaphyseal widening with cupping and fraying on radiograph, and bowing deformity of lower extremities. Panel C: Bone changes in primary hyperparathyroidism showing subperiosteal resorption of the phalanges (pathognomonic finding), salt-and-pepper skull appearance, brown tumor (osteoclastoma), and osteitis fibrosa cystica histology. Panel D: Pathophysiology of renal osteodystrophy showing the cascade from decreased GFR leading to phosphate retention, decreased vitamin D activation, secondary hyperparathyroidism, and resulting bone disease manifestations. --- ### IX. Connective Tissue Components and Collagen Collagen represents the most abundant protein family in the human body, providing structural framework for bones, tendons, ligaments, skin, blood vessels, and virtually all connective tissues. The collagen superfamily comprises at least 28 genetically distinct types, each with tissue-specific distribution and functional properties. Type I collagen predominates in bone, skin, tendon, and ligament, providing tensile strength to resist stretching forces. Type II collagen is the principal collagen of hyaline cartilage and the vitreous humor of the eye, contributing to the compressive resilience of these tissues. Type III collagen associates with type I in blood vessel walls and skin, providing structural integrity with greater elasticity. Type IV collagen is a major component of basement membranes throughout the body. Type V collagen regulates collagen fibril diameter and is found at cell surfaces. Collagen synthesis involves a complex multistep process occurring both intracellularly and extracellularly, with each step providing potential targets for disease or therapeutic intervention. Transcription of collagen genes produces messenger RNA encoding prepro-alpha chains, which are translated on ribosomes and translocated into the endoplasmic reticulum. Hydroxylation of specific proline and lysine residues by prolyl and lysyl hydroxylases requires vitamin C (ascorbic acid) as an essential cofactor. Glycosylation adds sugar groups to hydroxylysine residues. Three alpha chains then assemble into a triple-helix configuration called procollagen, stabilized by hydrogen bonds between hydroxyproline residues. Procollagen is secreted by exocytosis into the extracellular space. Procollagen peptidases cleave the N-terminal and C-terminal propeptides to produce tropocollagen. Finally, lysyl oxidase catalyzes covalent cross-linking between adjacent tropocollagen molecules, generating the collagen fibril with its characteristic tensile strength. Heritable disorders of collagen synthesis and structure produce a spectrum of connective tissue diseases with manifestations reflecting the affected collagen type and severity of the molecular defect. Osteogenesis imperfecta encompasses a group of disorders caused by mutations in type I collagen genes, characterized by bone fragility with recurrent fractures, often accompanied by blue sclerae (due to visible choroid through thin collagen), hearing loss (ossicular bone abnormality), and dentinogenesis imperfecta. Ehlers-Danlos syndromes comprise a heterogeneous group of conditions affecting various collagen types, characterized by joint hypermobility, skin hyperextensibility, and tissue fragility, with some types carrying risk of arterial rupture or organ perforation. Scurvy results from vitamin C deficiency impairing collagen hydroxylation, manifesting with impaired wound healing, bleeding gums, perifollicular hemorrhages, and corkscrew hairs. Alport syndrome involves mutations in type IV collagen, primarily affecting glomerular and cochlear basement membranes to produce progressive nephritis and sensorineural hearing loss. Beyond collagen, the extracellular matrix contains numerous other structural and functional proteins essential for tissue integrity. Elastin provides elastic recoil to tissues such as arterial walls, lungs, and skin, allowing stretch and recovery without permanent deformation. Elastin abnormalities underlie diseases including cutis laxa (loose, sagging skin) and supravalvular aortic stenosis associated with Williams syndrome. Fibronectin mediates cell adhesion to the extracellular matrix through binding to integrins, playing essential roles in wound healing and embryonic development. Laminin is a major basement membrane component linking cells to underlying matrix. Glycosaminoglycans including hyaluronic acid, chondroitin sulfate, dermatan sulfate, and heparan sulfate attract water and cations, providing tissue hydration and compressive resistance while also influencing cell behavior through growth factor binding. Panel A: Collagen synthesis pathway showing intracellular steps (transcription, translation, hydroxylation requiring vitamin C, glycosylation, triple helix formation) and extracellular steps (procollagen secretion, propeptide cleavage, cross-linking by lysyl oxidase, fibril assembly). Panel B: Triple helix structure of collagen showing three alpha chains wound around each other with glycine residues at every third position facing the center, and hydroxylated proline and lysine residues stabilizing the structure. Panel C: Clinical manifestations of collagen disorders comparing osteogenesis imperfecta (brittle bones, blue sclerae), Ehlers-Danlos syndrome (hypermobile joints, stretchable skin), and scurvy (bleeding gums, perifollicular hemorrhage, poor wound healing). Panel D: Distribution of major collagen types throughout the body with type I in bone, tendon, and skin; type II in cartilage; type III in blood vessels; and type IV in basement membranes. --- ### X. Muscle Structure and Function Muscle tissue is classified into three distinct types based on structure, control mechanisms, and anatomical location, each adapted for specific functional requirements. Skeletal muscle attaches to bones via tendons and is responsible for voluntary movement, postural maintenance, and heat generation through shivering thermogenesis. Cardiac muscle forms the myocardium and contracts rhythmically under autonomic regulation to pump blood through the circulatory system, exhibiting unique properties including autorhythmicity, gap junction-mediated electrical coupling, and resistance to fatigue. Smooth muscle comprises the walls of hollow organs and blood vessels, contracting involuntarily under autonomic and hormonal control to regulate blood flow, propel contents through the gastrointestinal tract, and perform other visceral functions. While sharing fundamental contractile mechanisms, these muscle types differ in cellular organization, calcium regulation, and contraction characteristics. Skeletal muscle demonstrates a hierarchical organization from the whole muscle organ through progressively smaller structural units to the molecular level of contractile proteins. The whole muscle is ensheathed by epimysium and subdivided into bundles called fascicles wrapped in perimysium. Each fascicle contains numerous muscle fibers (individual muscle cells), each surrounded by endomysium. The multinucleated muscle fiber contains hundreds to thousands of myofibrils, cylindrical structures approximately 1-2 micrometers in diameter that extend the length of the fiber. Myofibrils exhibit characteristic banding patterns arising from the regular arrangement of contractile proteins within sarcomeres, the fundamental functional units of muscle contraction. The sarcomere extends from one Z line to the next and contains interdigitating thick (myosin) and thin (actin) filaments whose interaction generates force. The sarcomere structure can be understood through its characteristic bands and zones visible on electron microscopy, each corresponding to specific protein arrangements. Z lines (from the German "Zwischen," meaning between) demarcate sarcomere boundaries and anchor thin filaments through alpha-actinin. The I band contains only thin filaments and appears light; it spans the region from the Z line to the beginning of thick filament overlap and shortens during contraction. The A band encompasses the entire length of thick filaments and maintains constant width during contraction because thick filament length remains unchanged. The H zone within the A band contains only thick filaments without thin filament overlap; it shortens during contraction as thin filaments slide further inward. The M line at the center of the sarcomere anchors thick filaments through myomesin and other proteins. The sliding filament theory explains muscle contraction as the active sliding of thin filaments past thick filaments without change in filament length. Skeletal muscle fibers are classified into types based on their contractile and metabolic properties, with the fiber type composition of individual muscles reflecting their functional demands. Type I fibers, also termed slow-twitch or slow oxidative fibers, contract slowly but are highly resistant to fatigue due to abundant mitochondria, myoglobin, and capillary supply supporting oxidative metabolism. These red fibers predominate in postural muscles and endurance athletes. Type IIa fibers exhibit intermediate properties with both oxidative and glycolytic capacity, providing fast contraction with moderate fatigue resistance. Type IIb (or IIx) fibers, also termed fast-twitch or fast glycolytic fibers, generate rapid, powerful contractions but fatigue quickly due to reliance on anaerobic glycolysis. These white fibers predominate in muscles requiring brief, intense activity. Fiber type composition is influenced by genetics but can shift modestly with training, as endurance exercise promotes transition toward more oxidative phenotypes. Panel A: Hierarchical organization of skeletal muscle from whole muscle through fascicles to individual fibers to myofibrils, with surrounding connective tissue layers (epimysium, perimysium, endomysium) illustrated at each level. Panel B: Sarcomere ultrastructure showing Z lines at boundaries, I bands (thin filaments only), A bands (thick filaments), H zone (thick filaments without overlap), and M line at center, with labels for actin thin filaments and myosin thick filaments. Panel C: Sliding filament mechanism of muscle contraction showing sarcomere at rest and contracted states, with thin filaments sliding past stationary thick filaments, shortening of I bands and H zone, and constant A band width. Panel D: Muscle fiber types comparison showing Type I (slow oxidative, red, rich in mitochondria and capillaries) versus Type IIb (fast glycolytic, white, fewer mitochondria), with graph comparing force generation and fatigue characteristics. --- ## Summary - Bone is composed of organic matrix (predominantly type I collagen, 35%) providing flexibility and inorganic mineral (hydroxyapatite, 65%) providing rigidity - Four bone cell types coordinate bone homeostasis: osteoblasts (formation), osteoclasts (resorption), osteocytes (mechanosensing), and bone lining cells (surface coverage) - The RANK/RANKL/OPG signaling system is the central pathway regulating osteoclast differentiation; therapeutic targeting has produced denosumab for osteoporosis - Synovial joints feature articular cartilage, synovial membrane, joint capsule, synovial fluid, and ligaments enabling low-friction movement with stability - Articular cartilage is avascular and composed of type II collagen, proteoglycans (especially aggrecan), and chondrocytes organized in distinct zones - Calcium homeostasis is regulated by PTH, vitamin D, and calcitonin acting on bone, kidney, and intestine to maintain serum ionized calcium - Osteoporosis is diagnosed by DXA with T-score less than or equal to -2.5; treatment includes bisphosphonates, denosumab, and anabolic agents - Osteomalacia results from defective mineralization due to vitamin D deficiency or phosphate depletion - Collagen synthesis requires vitamin C for hydroxylation; defects cause osteogenesis imperfecta, Ehlers-Danlos syndromes, and scurvy - Skeletal muscle organization proceeds from muscle to fascicle to fiber to myofibril to sarcomere; contraction occurs via the sliding filament mechanism --- ## Key Terms | Term | Definition | |------|------------| | Osteoblast | Bone-forming cell derived from mesenchymal stem cells that synthesizes osteoid matrix | | Osteoclast | Multinucleated bone-resorbing cell derived from monocyte-macrophage precursors | | Osteocyte | Most abundant bone cell; mechanosensor embedded within mineralized matrix | | Osteon | Functional unit of cortical bone consisting of concentric lamellae around a central Haversian canal | | RANKL | Receptor activator of NF-kappa-B ligand; essential signal for osteoclast differentiation | | Articular cartilage | Hyaline cartilage covering joint surfaces; composed of type II collagen and proteoglycans | | Proteoglycan | Macromolecule with core protein and glycosaminoglycan chains; provides compressive resistance | | T-score | Standard deviations from young adult mean bone mineral density used for osteoporosis diagnosis | | Hydroxyapatite | Calcium phosphate mineral comprising the inorganic component of bone | | Sarcomere | Fundamental contractile unit of skeletal muscle bounded by Z lines | --- *This content is subject to the [MIT License](https://opensource.org/licenses/MIT). © 2024–2026 Hibbert School of Medicine.*